From GlobeNewswire: 2025-04-16 07:00:00

EyePoint Pharmaceuticals, Inc. granted non-statutory stock options to four new employees outside the 2023 Long-Term Incentive Plan. Each employee received options to purchase up to 65,000 shares of EyePoint common stock at an exercise price of $5.67 per share. The options have a ten-year term and vest over four years based on continued service with EyePoint. EyePoint is focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, in Phase 3 global clinical trials for wet AMD and Phase 2 trials for DME. EyePoint is headquartered in Watertown, Massachusetts.



Read more at GlobeNewswire: EyePoint Pharmaceuticals Reports Inducement Grants Under